

Application No. 09/806,178  
Paper dated September 27, 2004  
In reply to USPTO Correspondence of April 26, 2004  
Attorney Docket No. 702-010411

### **REMARKS**

Claims 7 and 12-14 are currently pending in this application. Claim 7 has been amended. Claims 12-14 have been cancelled. No new matter has been added. In view of these amendments and of the following remarks, Applicants believe that all the asserted rejections are in condition for withdrawal and all the claims are in condition for allowance.

Claims 7 and 12-14 stand rejected under 35 U.S.C. 112, first paragraph, for purported lack of enablement. The Examiner asserts that, while the specification is enabling for a method for the treatment of focal cerebral ischemic infarction by administering an effective dosage of at least one  $\alpha$ 2-antiplasmin neutralizing protein selected from the group consisting of plasmin, mini-plasmin, and microplasmin, it does not reasonably provide enablement for practicing said method using other  $\alpha$ 2-antiplasmin neutralizing compounds, mutants, and hybrids thereof.

Additionally, claims 7, 13 and 14 stand rejected under 35 U.S.C. 112, first paragraph, for purported lack of written description. The Examiner asserts that claim 7 requires a " $\alpha$ 2-antiplasmin neutralizing compound" but does not require that the compound possess any particular conserved structure or other distinguishing feature, and that claims 13 and 14 require "one Kringle domain and mutants and hybrids thereof" but does not require that the mutants and hybrids possess any particular conserved structure or other distinguishing feature.


Accordingly, claim 7 has been amended to conform to the proposed Examiner's amendment contained in the previous Office Action. Additionally, claims 12-14 have been cancelled. Thus, because Applicants have accepted the proposed Examiner's amendment to claim 7, the above-described rejections have been obviated.

Application No. 09/806,178  
Paper dated September 27, 2004  
In reply to USPTO Correspondence of April 26, 2004  
Attorney Docket No. 702-010411

In view of the foregoing, amended claim 7 is patentable and in condition for allowance. Withdrawal of the asserted rejections and allowance of pending claim 7 is respectfully requested.

Respectfully submitted,

WEBB ZIESENHEIM LOGSDON  
ORKIN & HANSON, P.C.

By 

Barbara E. Johnson  
Registration No. 31,198  
Attorney for Applicants  
700 Koppers Building  
436 Seventh Avenue  
Pittsburgh, PA 15219-1818  
Telephone: 412-471-8815  
Facsimile: 412-471-4094  
E-mail: [webblaw@webblaw.com](mailto:webblaw@webblaw.com)